33,332 Shares in LivaNova PLC $LIVN Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 33,332 shares of the company’s stock, valued at approximately $1,746,000. Tudor Investment Corp ET AL owned about 0.06% of LivaNova at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of LIVN. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. Quarry LP acquired a new stake in LivaNova during the 3rd quarter worth approximately $36,000. UMB Bank n.a. raised its holdings in LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after buying an additional 306 shares during the period. Finally, Bayforest Capital Ltd raised its holdings in LivaNova by 44.8% during the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after buying an additional 284 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

NASDAQ LIVN opened at $62.78 on Monday. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 0.29. LivaNova PLC has a 12-month low of $32.65 and a 12-month high of $71.92. The company has a market capitalization of $3.43 billion, a PE ratio of -14.08 and a beta of 0.97. The firm’s 50 day moving average is $64.85 and its 200-day moving average is $60.76.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $360.92 million for the quarter, compared to the consensus estimate of $354.31 million. During the same period last year, the company earned $0.81 earnings per share. The firm’s revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several research analyst reports. Robert W. Baird set a $75.00 target price on shares of LivaNova in a report on Tuesday, December 16th. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a report on Wednesday, February 25th. Barclays raised their target price on shares of LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Mizuho raised their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.78.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.